The Pearsanta’s MET diagnostic test uses a blood-based biomarker for detecting mitochondrial DNA for diagnosing endometriosis ...

Aditxt (NASDAQ: ADTX) , an innovation platform dedicated to accelerating promising health innovations, has reported that its Acquisition target, Evofem Biosciences (OTCQB: EVFM) , a women's health ...

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, and its majority-owned subsidiary, Pearsanta Inc., have signed a market development collaboration ...

Aditxt (NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising <a target=_blank href= ...

Under the Agreement, Evofem and Pearsanta will collaboratively develop a comprehensive go-to-market strategy and MET commercial plan ahead of the planned U.S. launch in mid-2025. To date, over 300 ...

Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today announced that its acquisition target, Evofem Biosciences, ...

Despite insufficient data, writing panel will give recommendations for preparation, transfer, and follow-up for youth with ...

Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for ...